Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

Challenges and motivators for male partner involvement in prenatal care for HIV testing in a tertiary setting in Brazil.

Yeganeh N, Kerin T, Simon M, Nielsen-Saines K, Klausner JD, Santos B, Melo M, Fitter S, Gorbach PM.

Int J STD AIDS. 2019 Aug;30(9):875-884. doi: 10.1177/0956462419845225. Epub 2019 Jun 3. No abstract available.

2.

Management of Hyperkalemia With Insulin and Glucose: Pearls for the Emergency Clinician.

Moussavi K, Fitter S, Gabrielson SW, Koyfman A, Long B.

J Emerg Med. 2019 Jul;57(1):36-42. doi: 10.1016/j.jemermed.2019.03.043. Epub 2019 May 11.

PMID:
31084947
3.

Safety of Peripheral Line Administration of 3% Hypertonic Saline and Mannitol in the Emergency Department.

Mesghali E, Fitter S, Bahjri K, Moussavi K.

J Emerg Med. 2019 Apr;56(4):431-436. doi: 10.1016/j.jemermed.2018.12.046. Epub 2019 Feb 8.

PMID:
30745195
4.

mTORC1 plays an important role in osteoblastic regulation of B-lymphopoiesis.

Martin SK, Fitter S, El Khawanky N, Grose RH, Walkley CR, Purton LE, Ruegg MA, Hall MN, Gronthos S, Zannettino ACW.

Sci Rep. 2018 Sep 28;8(1):14501. doi: 10.1038/s41598-018-32858-5.

5.

Osteopontin in the pathophysiology of obesity: Is Opn a fat cell foe?

Fitter S, Zannettino ACW.

Obes Res Clin Pract. 2018 May - Jun;12(3):249-250. doi: 10.1016/j.orcp.2018.06.004. No abstract available.

PMID:
29914635
6.

Osteocalcin-dependent regulation of glucose metabolism and fertility: Skeletal implications for the development of insulin resistance.

Tangseefa P, Martin SK, Fitter S, Baldock PA, Proud CG, Zannettino ACW.

J Cell Physiol. 2018 May;233(5):3769-3783. doi: 10.1002/jcp.26163. Epub 2017 Sep 18. Review.

PMID:
28834550
7.

mTORC1 Plays an Important Role in Skeletal Development by Controlling Preosteoblast Differentiation.

Fitter S, Matthews MP, Martin SK, Xie J, Ooi SS, Walkley CR, Codrington JD, Ruegg MA, Hall MN, Proud CG, Gronthos S, Zannettino ACW.

Mol Cell Biol. 2017 Mar 17;37(7). pii: e00668-16. doi: 10.1128/MCB.00668-16. Print 2017 Apr 1.

8.

The Mesenchymal Precursor Cell Marker Antibody STRO-1 Binds to Cell Surface Heat Shock Cognate 70.

Fitter S, Gronthos S, Ooi SS, Zannettino AC.

Stem Cells. 2017 Apr;35(4):940-951. doi: 10.1002/stem.2560. Epub 2017 Jan 23.

9.

Tetraspanin 7 (TSPAN7) expression is upregulated in multiple myeloma patients and inhibits myeloma tumour development in vivo.

Cheong CM, Chow AW, Fitter S, Hewett DR, Martin SK, Williams SA, To LB, Zannettino AC, Vandyke K.

Exp Cell Res. 2015 Mar 1;332(1):24-38. doi: 10.1016/j.yexcr.2015.01.006. Epub 2015 Jan 28.

PMID:
25637218
10.

The effect of the PI3K inhibitor BKM120 on tumour growth and osteolytic bone disease in multiple myeloma.

Martin SK, Gan ZY, Fitter S, To LB, Zannettino AC.

Leuk Res. 2015 Mar;39(3):380-7. doi: 10.1016/j.leukres.2014.12.015. Epub 2015 Jan 7.

PMID:
25624048
11.

Brief report: the differential roles of mTORC1 and mTORC2 in mesenchymal stem cell differentiation.

Martin SK, Fitter S, Dutta AK, Matthews MP, Walkley CR, Hall MN, Ruegg MA, Gronthos S, Zannettino AC.

Stem Cells. 2015 Apr;33(4):1359-65. doi: 10.1002/stem.1931.

12.

The effect of the dual PI3K and mTOR inhibitor BEZ235 on tumour growth and osteolytic bone disease in multiple myeloma.

Gan ZY, Fitter S, Vandyke K, To LB, Zannettino AC, Martin SK.

Eur J Haematol. 2015 Apr;94(4):343-54. doi: 10.1111/ejh.12436. Epub 2014 Sep 17.

PMID:
25179233
13.

Protein kinase activity of phosphoinositide 3-kinase regulates cytokine-dependent cell survival.

Thomas D, Powell JA, Green BD, Barry EF, Ma Y, Woodcock J, Fitter S, Zannettino AC, Pitson SM, Hughes TP, Lopez AF, Shepherd PR, Wei AH, Ekert PG, Guthridge MA.

PLoS Biol. 2013;11(3):e1001515. doi: 10.1371/journal.pbio.1001515. Epub 2013 Mar 19.

14.

Prospective histomorphometric and DXA evaluation of bone remodeling in imatinib-treated CML patients: evidence for site-specific skeletal effects.

Vandyke K, Fitter S, Drew J, Fukumoto S, Schultz CG, Sims NA, Yeung DT, Hughes TP, Zannettino AC.

J Clin Endocrinol Metab. 2013 Jan;98(1):67-76. doi: 10.1210/jc.2012-2426. Epub 2012 Nov 8.

PMID:
23144472
15.

Double-blind, placebo-controlled randomized trial with adalimumab for treatment of juvenile onset ankylosing spondylitis (JoAS): significant short term improvement.

Horneff G, Fitter S, Foeldvari I, Minden K, Kuemmerle-Deschner J, Tzaribacev N, Thon A, Borte M, Ganser G, Trauzeddel R, Huppertz HI.

Arthritis Res Ther. 2012 Oct 24;14(5):R230. doi: 10.1186/ar4072.

16.

Suppression of PDGF-induced PI3 kinase activity by imatinib promotes adipogenesis and adiponectin secretion.

Fitter S, Vandyke K, Gronthos S, Zannettino AC.

J Mol Endocrinol. 2012 May 8;48(3):229-40. doi: 10.1530/JME-12-0003. Print 2012 Jun.

PMID:
22474082
17.

The tyrosine kinase inhibitor dasatinib (SPRYCEL) inhibits chondrocyte activity and proliferation.

Vandyke K, Fitter S, Zannettino AC.

Blood Cancer J. 2011 Feb;1(2):e2. doi: 10.1038/bcj.2011.1. Epub 2011 Feb 4. No abstract available.

18.

Diverticular fistulation is associated with nicorandil usage.

McDaid J, Reichl C, Hamzah I, Fitter S, Harbach L, Savage AP.

Ann R Coll Surg Engl. 2010 Sep;92(6):463-5. doi: 10.1308/003588410X12699663904673.

19.

NVP-BEZ235, a dual pan class I PI3 kinase and mTOR inhibitor, promotes osteogenic differentiation in human mesenchymal stromal cells.

Martin SK, Fitter S, Bong LF, Drew JJ, Gronthos S, Shepherd PR, Zannettino AC.

J Bone Miner Res. 2010 Oct;25(10):2126-37. doi: 10.1002/jbmr.114.

20.

Plasma adiponectin levels are markedly elevated in imatinib-treated chronic myeloid leukemia (CML) patients: a mechanism for improved insulin sensitivity in type 2 diabetic CML patients?

Fitter S, Vandyke K, Schultz CG, White D, Hughes TP, Zannettino AC.

J Clin Endocrinol Metab. 2010 Aug;95(8):3763-7. doi: 10.1210/jc.2010-0086. Epub 2010 May 13.

PMID:
20466781
21.

The tyrosine kinase inhibitor dasatinib dysregulates bone remodeling through inhibition of osteoclasts in vivo.

Vandyke K, Dewar AL, Diamond P, Fitter S, Schultz CG, Sims NA, Zannettino AC.

J Bone Miner Res. 2010 Aug;25(8):1759-70. doi: 10.1002/jbmr.85.

22.

Dysregulation of bone remodeling by imatinib mesylate.

Vandyke K, Fitter S, Dewar AL, Hughes TP, Zannettino AC.

Blood. 2010 Jan 28;115(4):766-74. doi: 10.1182/blood-2009-08-237404. Epub 2009 Nov 4. Review.

23.

Imatinib mesylate causes growth plate closure in vivo.

Vandyke K, Dewar AL, Fitter S, Menicanin D, To LB, Hughes TP, Zannettino AC.

Leukemia. 2009 Nov;23(11):2155-9. doi: 10.1038/leu.2009.150. Epub 2009 Jul 23. No abstract available.

PMID:
19626049
24.

Safety and efficacy of once weekly etanercept 0.8 mg/kg in a multicentre 12 week trial in active polyarticular course juvenile idiopathic arthritis.

Horneff G, Ebert A, Fitter S, Minden K, Foeldvari I, K├╝mmerle-Deschner J, Thon A, Girschick HJ, Weller F, Huppertz HI.

Rheumatology (Oxford). 2009 Aug;48(8):916-9. doi: 10.1093/rheumatology/kep122. Epub 2009 May 29.

PMID:
19483091
25.

Heat shock protein-90 beta is expressed at the surface of multipotential mesenchymal precursor cells: generation of a novel monoclonal antibody, STRO-4, with specificity for mesenchymal precursor cells from human and ovine tissues.

Gronthos S, McCarty R, Mrozik K, Fitter S, Paton S, Menicanin D, Itescu S, Bartold PM, Xian C, Zannettino AC.

Stem Cells Dev. 2009 Nov;18(9):1253-62. doi: 10.1089/scd.2008.0400.

PMID:
19327008
26.

Therapeutic concentrations of dasatinib inhibit in vitro osteoclastogenesis.

Vandyke K, Dewar AL, Farrugia AN, Fitter S, Bik To L, Hughes TP, Zannettino AC.

Leukemia. 2009 May;23(5):994-7. doi: 10.1038/leu.2008.356. Epub 2008 Dec 18. No abstract available.

PMID:
19092851
27.

A novel monoclonal antibody (STRO-3) identifies an isoform of tissue nonspecific alkaline phosphatase expressed by multipotent bone marrow stromal stem cells.

Gronthos S, Fitter S, Diamond P, Simmons PJ, Itescu S, Zannettino AC.

Stem Cells Dev. 2007 Dec;16(6):953-63.

PMID:
18158854
28.

Long-term imatinib therapy promotes bone formation in CML patients.

Fitter S, Dewar AL, Kostakis P, To LB, Hughes TP, Roberts MM, Lynch K, Vernon-Roberts B, Zannettino AC.

Blood. 2008 Mar 1;111(5):2538-47. Epub 2007 Nov 27.

29.

Deconvolution of a complex target using DNA aptamers.

Fitter S, James R.

J Biol Chem. 2005 Oct 7;280(40):34193-201. Epub 2005 Aug 4.

30.

Characterization of mice lacking the tetraspanin superfamily member CD151.

Wright MD, Geary SM, Fitter S, Moseley GW, Lau LM, Sheng KC, Apostolopoulos V, Stanley EG, Jackson DE, Ashman LK.

Mol Cell Biol. 2004 Jul;24(13):5978-88.

31.

Differential tissue expression of epitopes of the tetraspanin CD151 recognised by monoclonal antibodies.

Geary SM, Cambareri AC, Sincock PM, Fitter S, Ashman LK.

Tissue Antigens. 2001 Sep;58(3):141-53.

PMID:
11703821
32.

Analysis of the CD151-alpha3beta1 integrin and CD151-tetraspanin interactions by mutagenesis.

Berditchevski F, Gilbert E, Griffiths MR, Fitter S, Ashman L, Jenner SJ.

J Biol Chem. 2001 Nov 2;276(44):41165-74. Epub 2001 Jul 30.

35.
36.

Molecular cloning of cDNA encoding a novel platelet-endothelial cell tetra-span antigen, PETA-3.

Fitter S, Tetaz TJ, Berndt MC, Ashman LK.

Blood. 1995 Aug 15;86(4):1348-55.

37.

A combined PCR and selective enrichment method for rapid detection of Listeria monocytogenes.

Fitter S, Heuzenroeder M, Thomas CJ.

J Appl Bacteriol. 1992 Jul;73(1):53-9.

PMID:
1512178

Supplemental Content

Loading ...
Support Center